John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, gives an overview of the results of MOMENTUM, a Phase III study comparing momelotinib versus danazol in anemic and symptomatic patients with myelofibrosis (MF) previously treated with a JAK inhibitor (NCT04173494). The study reported that it met its primary endpoint of Total Symptom Score (TSS) response rate, as well as its secondary endpoints of transfusion independence and splenic response rate. The full results will be released at this year’s ASCO and EHA meetings. This interview took place virtually.
Research funding paid to Prof. Mascarenhas’ institution from Incyte, Novartis, Celgene, BMS, CTI Bio, Merck, Roche, Kartos, PharmaEssentia, Abbvie, and Geron. Consulting fees from Novartis, Incyte, CTI Bio, Constellation, Abbvie, Roche, Kartos, PharmaEssentia, Sierra Onc, Galecto, GSK, Karyopharm, Celgene, Geron and BMS.